23Jan
Blog: Cooley's 2019 Life Sciences M&A Year in Review
2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in...
By:
Cooley LLP
Related
On June 19, 2020, the Hungarian Competition Authority (“GVH”) adopted a decision providing guidanc...
Read More >
I have been asked by more than one frustrated California employer how to avoid or reduce employment ...
Read More >
Most deals are approved, but new rules covering more types of transactions and requiring mandatory f...
Read More >
Recent law changes can provide portfolio company liquidity and/or require reconsideration of 2018–2...
Read More >
As Canada takes steps towards economic recovery from the COVID-19 pandemic, the health and safety co...
Read More >
On December 19, 2019, the U.S. General Services Administration (“GSA”) issued a final rule which a...
Read More >